

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001682093
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Galecto, Inc.
SEC File Number 001-39655
Address of Issuer 75 State Street
Suite 100
Boston
MASSACHUSETTS
02109
Phone 45-70-70-52-10
Name of Person for Whose Account the Securities are To Be Sold OrbiMed Israel Partners II, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Bank of America One Bryant Park New York NY 10036	631048	389357.00	27112697	08/21/2023	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from	Is this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	---------------------	---------	---------------------	-------------------------------	-----------------	---------------------

	Whom Acquired	a Gift?		
Common Stock	10/23/2018 Private placement	Issuer	<input type="checkbox"/>	631048 10/23/2018 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
OrbiMed Israel Partners II, L.P. 5 Hahoshlim St. Building B, 1st Floor Herzliya Pituach L3 4672405	Common Stock	07/13/2023	52800	126720.00
OrbiMed Israel Partners II, L.P. 5 Hahoshlim St. Building B, 1st Floor Herzliya Pituach L3 4672405	Common Stock	07/25/2023	4700	13724.00
OrbiMed Israel Partners II, L.P. 5 Hahoshlim St. Building B, 1st Floor Herzliya Pituach L3 4672405	Common Stock	07/31/2023	29700	89100.00
OrbiMed Israel Partners II, L.P. 5 Hahoshlim St. Building B, 1st Floor Herzliya Pituach L3 4672405	Common Stock	08/15/2023	248819	186614.00

144: Remarks and Signature

Remarks OrbiMed Israel GP II, L.P. is the general partner of OrbiMed Israel Partners II, L.P. OrbiMed Advisors Israel II Limited is the general partner of OrbiMed Israel GP II, L.P.

Date of Notice 08/21/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors II Limited, general partner of the general partner of OrbiMed Israel Partners II, L.P.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)